Combination Ketamine and Propofol vs Propofol for Emergency Department Sedation: A Prospective Randomized Trial
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to determine if procedural sedation utilizing a 1:1 mixture of propofol and ketamine is equivalent in complications, patient and physician satisfaction, post-procedure pain level, and procedural outcome to propofol sedation alone.
| Condition | Intervention |
|---|---|
|
Sedation |
Procedure: 1:1 ketamine-propofol mixture sedation Procedure: Propofol Sedation |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Single Group Assignment Masking: Single Blind (Subject) Primary Purpose: Treatment |
| Official Title: | Combination Ketamine and Propofol vs Propofol for Emergency Department Sedation: A Prospective Randomized Trial |
- airway complications [ Time Frame: within 12 months of study completion ] [ Designated as safety issue: Yes ]The use of any: Adjunctive airway device (nasopharyngeal airway (NPA)/oropharyngeal airway (OPA), Jaw thrust or other airway maneuver., Use of Bag Valve Mask (BVM) for ventilation and reversal medications (i.e. Narcan).
- subclinical respiratory depression [ Time Frame: within 12 months of study completion ] [ Designated as safety issue: Yes ]subclinical respiratory depression (hypoxemia despite supplemental oxygen noted on pulse-oximetry, loss of End-tidal carbon dioxide concentration in the expired air (ETCO2) waveform for 15 seconds or greater, systolic pressure (SBP) below 80mm Hg, cardiac arrhythmias.)
- satisfaction [ Time Frame: within 12 months of study completion ] [ Designated as safety issue: No ]Following sedation, questionnaires were completed by the sedating physician, any consultant physician, nurse, and patient
| Estimated Enrollment: | 130 |
| Study Start Date: | June 2010 |
| Estimated Study Completion Date: | June 2013 |
| Estimated Primary Completion Date: | December 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Active Comparator: 1:1 ketamine - propofol mixture |
Procedure: 1:1 ketamine-propofol mixture sedation
Prepare Ketamine and Propofol 10mg/cc of ketamine 10mg/cc of propofol mix 1:1 in 10 or 20 cc syringes Sedation Initial dose 0.05 cc / kg IV bolus. Repeat dose 0.025 - 0.05 every 60-90 seconds as needed to reach and maintain target level of sedation. May round to nearest 0.5-1 cc. Note - 1 cc = 5mg of propofol and 5mg of ketamine Other Name: Ketofol
|
|
Active Comparator: propofol
propofol
|
Procedure: Propofol Sedation
Prepare Propofol 10mg/cc of propofol 10 or 20 cc syringes Sedation Initial dose 0.05 cc / kg IV bolus over 30 seconds. Repeat dose 0.025 - 0.05 cc/kg every 30-60 seconds as needed to reach and maintain target level of sedation. May round to nearest 0.5 cc Note - 1 cc = 10 mg of propofol Other Name: Propofol
|
Show Detailed Description
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- English speaking patients eighteen and older who present to the University of Utah Emergency Department and require, in their treating physician's opinion, procedural sedation for a procedure or radiologic study performed in the Emergency Department.
Exclusion Criteria:
- Include prior sensitization or allergic reaction to propofol, ketamine, soy or egg products; hemodynamic instability; clinical evidence of head injury, increased intracranial or intraocular pressure; use of drugs known to interact with either study agent, pregnancy with a live intra-uterine pregnancy (i.e. undergoing Dilation and Curettage for intrauterine fetal demise or spontaneous abortion is not an exclusion criteria).
Contacts and Locations| Contact: Virgil Davis, MD | 8015812417 | Virgil.Davis@hsc.utah.edu |
| Contact: Anas Sawas, MS, MPH | (801) 839-4742 | ansawas@hsc.utah.edu |
| United States, Utah | |
| University of Utah | Recruiting |
| Salt Lake City, Utah, United States, 84132 | |
| Contact: Virgil Davis, MD 801-581-2417 virgil.davis@hsc.utah.edu | |
| Principal Investigator: Virgil Davis, MD | |
| Principal Investigator: | Scott Youngquist, MD MSc | University of Utah |
| Principal Investigator: | Virgil Davis, MD | University of Utah |
| Principal Investigator: | Troy Madsen, MD | University of Utah |
| Principal Investigator: | Anas Sawas, MS MPH | University of Utah |
| Principal Investigator: | Matthew Ahern, DO | University of Utah |
| Principal Investigator: | Camille Broadwater-Hollifield, M.P.H. | University of Utah, Division of Emergency Medicine |
More Information
Publications:
| Responsible Party: | Virgil Davis, principal investigator, University of Utah |
| ClinicalTrials.gov Identifier: | NCT01269307 History of Changes |
| Other Study ID Numbers: | 39736 |
| Study First Received: | December 10, 2010 |
| Last Updated: | August 15, 2012 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by University of Utah:
|
Anesthesia Pain Procedural sedation Airway/Anesthesia/Analgesia |
Additional relevant MeSH terms:
|
Emergencies Disease Attributes Pathologic Processes Ketamine Propofol Anesthetics, Dissociative Anesthetics, Intravenous Anesthetics, General Anesthetics Central Nervous System Depressants Physiological Effects of Drugs |
Pharmacologic Actions Central Nervous System Agents Therapeutic Uses Excitatory Amino Acid Antagonists Excitatory Amino Acid Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Analgesics Sensory System Agents Peripheral Nervous System Agents Hypnotics and Sedatives |
ClinicalTrials.gov processed this record on May 16, 2013